PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers

Future Oncology

Volumn 6, Issue 4, 2010, Pages 485-486

  Stebbing, Justin ^a   Ellis, Paul ^b   Tutt, Andrew ^c  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

BRCA; Breast cancer; PARP inhibitor; Triple negative

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; DNA DAMAGE; DNA REPAIR; DRUG STABILITY; EDITORIAL; FATIGUE; GENE MUTATION; HAZARD RATIO; HUMAN; MUTAGENESIS; NAUSEA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

EID: 77950604063     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.27     Document Type: Editorial

References (14)

1. Lindahl T: Instability and decay of the primary structure of DNA. Nature 362(6422), 709-715 (1993). (Pubitemid 23125973)
2. McCabe N, Turner NC, Lord CJ et al.: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66(16), 8109-8115 (2006). (Pubitemid 44299177)
3. Gudmundsdottir K, Ashworth A: The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25(43), 5864-5874 (2006). (Pubitemid 44453442)
4. Farmer H, McCabe N, Lord CJ et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035), 917-921 (2005). (Pubitemid 40559006)
5. Bryant HE, Schultz N, Thomas HD et al.: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434(7035), 913-917 (2005). (Pubitemid 40559005)
6. Fong PC, Boss DS, Yap TA et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361(2), 123-134 (2009).
7. Tutt A, Robson M, Garber JE, Domchek S: Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J. Clin. Oncol. 27(Suppl. Abstract CRA501), S18 (2009).
8. O'Shaughnessy JO, Osborne C, Pippen J, Yoffe M: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol. 27(Suppl. Abstract 3), S18 (2009).
9. Audeh MW, Penson RT, Friedlander M, Powell B: Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. J. Clin. Oncol. 27(Suppl. Abstract 5500), S15 (2009).
10. Sakai W, Swisher EM, Karlan BY et al.: Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451(7182), 1116-1120 (2008). (Pubitemid 351317449)
11. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T: Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68(8), 2581-2586 (2008). (Pubitemid 351556255)
12. Edwards SL, Brough R, Lord CJ et al.: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111-1115 (2008). (Pubitemid 351317441)
13. Ashworth A: Drug resistance caused by reversion mutation. Cancer Res. 68(24), 10021-10023 (2008).
14. Ashworth A: A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26(22), 3785-3790 (2008).